Cogent Biosciences expects to file a new drug application for bezuclastinib in gastrointestinal stromal tumors early next ...

The mid-stage failure was unexpected to analysts at BMO Capital Markets, who viewed ‘770 as mostly derisked given its similar ...

Data presented at this year’s American Heart Association Scientific Sessions in New Orleans underline rapid advancements in ...

Representatives from companies such as Sanofi and Forge Biologics point to the potential for PreCheck to drive activation of ...

Kezar Life Sciences suffered multiple clinical holds and four patient deaths in a trial testing zetomipzomib for lupus—a ...

After a leading study caused the FDA to slap its most stringent warning on hormone replacement therapies for menopause more ...

The White House may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...

MeiraGTx Holdings is licensing a genetic eye disease medicine to Eli Lilly in a deal worth up to $475 million.

The cholesterol-lowering drug is part of a suite of medicines that also includes MariTide and that Amgen Chief Medical ...

Ionis is planning a supplemental submission by the end of the year to expand Tryngolza into severe hypertriglyceridemia. If ...

“No need for a reunion show: This seasons Real Housewives of Biopharma comes to a close with Pfizer’s winning bid for Metsera ...

Multiple analyst firms were impressed by the Phase III data, which showed that Merck’s oral PCSK9 inhibitor can lower ...